- Finance and business development veteran and founding member of CAMP4 leadership team -

CAMP4 Therapeutics, a biotechnology company harnessing the power of regulatory RNAs to upregulate genes and restore healthy expression, today announced that it has appointed Kelly Gold as its Chief Financial Officer. Ms. Gold, who currently serves as CAMP4’s Chief Business Officer and Senior Vice President of Finance, will lead all corporate finance and financial operations and will oversee relationships with financial institutions and investors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220419005098/en/

Kelly Gold, Chief Financial Officer, CAMP4 Therapeutics (Photo: Business Wire)

“Kelly is an astute financial executive and adept leader who has made significant contributions to the company, including playing a key role in raising a combined $90 million through our financings to date and in establishing the structure enabling CAMP4 to evolve into a mature, independent financial organization,” said Josh Mandel-Brehm, CEO of CAMP4. “Her deep skill set and intimate understanding of all aspects of our business and strategy will continue to be a tremendous asset to CAMP4 as we continue to advance our pipeline of precise, programmable therapeutic candidates targeting regulatory RNA and expand our discovery platform.”

Ms. Gold joined CAMP4 in 2017 and has held roles of increasing responsibility leading the Business Development and Finance functions. She has extensive knowledge of CAMP4’s financial organization and experience leading business development, operations, accounting, investor relations and corporate communications functions.

Prior to joining CAMP4, Ms. Gold held various roles in corporate finance and business planning at Biogen, where she provided financial leadership for the company’s late-stage and marketed rare disease programs. Prior to Biogen, Ms. Gold worked in both the healthcare and Latin American investment banking groups at Deutsche Bank. Ms. Gold began her career as a mechanical engineer designing biocontainment systems for Biosafety Level 4 research facilities. She holds bachelor’s degrees in biochemistry and mechanical engineering from Queen’s University in Ontario, as well as an MBA from the MIT Sloan School of Management.

“As an early member of the CAMP4 team and someone who has always loved operating at the intersection of science and business, I am excited to continue to build the company as CFO and ensure we are equipped for and successful in our next phase of growth,” said Ms. Gold. “We are pioneering a new approach to the regulation of genes in a very specific way that holds tremendous potential benefit for patients with genetic diseases and potential value for our investors.”

CAMP4 combines its proprietary RNA Actuating Platform (RAP) with state-of-the-art oligonucleotide technology to develop RNA Actuators, precise and programmable therapeutics that uniquely upregulate gene expression at the transcriptional level. CAMP4’s approach targets a new class of RNA known as regulatory RNAs (“regRNAs”) that control the expression of mRNA, making this approach applicable to any genetic disease whereby a small increase in gene output can lead to meaningful therapeutic outcomes. CAMP4’s current pipeline is focused on diseases where oligonucleotides have proven safe and effective, including CNS and liver diseases, with the potential to expand to a broad array of tissues.

About CAMP4 Therapeutics

At CAMP4, we are pioneering a novel approach to programmable therapeutics. We combine a deep understanding of regulatory RNA and gene expression with a complementary and customizable oligonucleotide modality. Our RNA Actuating Platform’s proprietary insights enable us to harness the power of RNA to upregulate the expression of genes and unlock the potential to create treatments for hundreds of diseases affecting millions of patients. Learn more about us at www.CAMP4tx.com and follow us @CAMP4tx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005098/en/